2024 transparency of funding of UK Patient Groups

Lymphoma Action

In 2024 we gave a grant of £20,000 to support their Healthcare Professional Education training course in Oxford and patient support materials. Our funding represented less than 1% of their overall income.

Leukaemia Care

In 2024 we gave a grant of £39,976 to support an additional part time telephone helpline nurse. This was the first annual payment of a three-year agreement. Our funding represented 1.62% of their overall income.

Blood Cancer UK

In 2024 we gave a grant of £15,000 to help support the expansion of their clinical trials support service. Our funding represented less than 1% of their overall income.

WMUK

In 2024 we gave a grant of £135,000 to help with projects to strengthen their patient support services. Our funding represented 28% of their overall income.

CLL Support Association

In 2024 we gave a grant of £20,000 to help support their 20^th anniversary patient conferences and educational materials. Our funding represented 9.89% of their overall income.

We're pleased to share that
BeiGene is now BeOne Medicines UK, Ltd.

While our name has changed, our values and purpose remain the same.

We're as committed as ever to our mission: to build the first next-generation oncology company - one that expands access to the highest quality therapies for more people around the world through courage, persistent innovation, and by challenging the status quo.

This change does not affect any existing agreements or day-to-day operations. You can continue to rely on the same dedication, collaboration, and shared goals that define our company.

Look out for our new logo - it reflects our renewed identity and vision, and symbolises the goals we're striving toward together.